Literature DB >> 26501510

Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.

Loren S Jack, Mohammad Ali Sadiq, Diana V Do, Quan Dong Nguyen.   

Abstract

Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26501510     DOI： 10.1159/000438954

Source DB:  PubMed          Journal:  Dev Ophthalmol        ISSN： 0250-3751


  9 in total

1.  Stable Retinoid Analogue Targeted Dual pH-Sensitive Smart Lipid ECO/pDNA Nanoparticles for Specific Gene Delivery in the Retinal Pigment Epithelium.

Authors:  Da Sun; Rebecca M Schur; Avery E Sears; Song-Qi Gao; Wenyu Sun; Amirreza Naderi; Timothy Kern; Krzysztof Palczewski; Zheng-Rong Lu
Journal:  ACS Appl Bio Mater       Date:  2020-04-03

2.  Proposal of a simple optical coherence tomography-based scoring system for progression of age-related macular degeneration.

Authors:  Jianqin Lei; Siva Balasubramanian; Nizar Saleh Abdelfattah; Muneeswar G Nittala; SriniVas R Sadda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-05-22       Impact factor: 3.117

3.  RPE65 has an additional function as the lutein to meso-zeaxanthin isomerase in the vertebrate eye.

Authors:  Rajalekshmy Shyam; Aruna Gorusupudi; Kelly Nelson; Martin P Horvath; Paul S Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

4.  Stem Cell-based Treatment Strategies for Degenerative Diseases of the Retina.

Authors:  Deepthi S Rajendran Nair; Biju B Thomas
Journal:  Curr Stem Cell Res Ther       Date:  2022       Impact factor: 3.758

Review 5.  Complement system and age-related macular degeneration: drugs and challenges.

Authors:  Jiali Wu; Xiaodong Sun
Journal:  Drug Des Devel Ther       Date:  2019-07-19       Impact factor: 4.162

6.  Automated detection and classification of early AMD biomarkers using deep learning.

Authors:  Sajib Saha; Marco Nassisi; Mo Wang; Sophiana Lindenberg; Yogi Kanagasingam; Srinivas Sadda; Zhihong Jewel Hu
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

7.  Evolving Patterns of Hyperfluorescent Fundus Autofluorescence Accompany Retinal Atrophy in the Rat and Mimic Atrophic Age-Related Macular Degeneration.

Authors:  Natalie Pankova; David Sung Hyeon Baek; Xu Zhao; Hai Wang; Matthew-Mina Reyad; Huiyuan Liang; Rahul Joshi; Shelley Romayne Boyd
Journal:  Transl Vis Sci Technol       Date:  2022-03-02       Impact factor: 3.283

8.  The novel visual cycle inhibitor (±)-RPE65-61 protects retinal photoreceptors from light-induced degeneration.

Authors:  Yuhong Wang; Xiang Ma; Parthasarathy Muthuraman; Arun Raja; Aravindan Jayaraman; Konstantin Petrukhin; Christopher L Cioffi; Jian-Xing Ma; Gennadiy Moiseyev
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

9.  Regulation of C3 Activation by the Alternative Complement Pathway in the Mouse Retina.

Authors:  Jennifer A E Williams; Dimitris Stampoulis; Chloe E Gunter; John Greenwood; Peter Adamson; Stephen E Moss
Journal:  PLoS One       Date:  2016-08-26       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.